Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 6/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664100 | 0.89 | CCR3 (0.43) | PER2CNR2AGTR1AGTR2TBXA2R | |
| SCHEMBL661691 | 0.89 | PER2 (0.43) | PER2CNR2AGTR1AGTR2CRY2 | |
| SCHEMBL1666151 | 0.87 | PER2 (0.43) | PER2AGTR1AGTR2TBXA2RCRY2 | |
| SCHEMBL661430 | 0.85 | CNR2 (0.40) | CNR2PPARGHDAC1 | |
| SCHEMBL662975 | 0.85 | LMNA (0.48) | AGTR1AGTR2NOS3NOS1NOS2 | |
| SCHEMBL661623 | 0.85 | PER2 (0.42) | PER2CNR2TBXA2RCRY2GNRHR | |
| SCHEMBL662280 | 0.85 | PER2 (0.44) | PER2CNR2AGTR1AGTR2CRY2 | |
| SCHEMBL663094 | 0.84 | PER2 (0.41) | PER2CNR2AGTR1AGTR2TBXA2R | |
| SCHEMBL4405507 | 0.80 | PER2 (0.38) | PER2CNR2TBXA2RCRY2 | |
| SCHEMBL661457 | 0.80 | PPARG (0.39) | CNR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763644-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-07-27 | — | — | US | claimed |
| EP-2050736-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | claimed |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. | 2008-04-03 | — | — | US | claimed |
| JP-2007513105-A | — | — | 2007-05-24 | — | — | JP | claimed |
| CN-1906160-A | Imidazole derivatives, processes for preparing them and their uses | UCB SA (BE) | 2007-01-31 | — | — | CN | claimed |
| EP-1706376-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-10-04 | — | — | EP | claimed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | claimed |
| WO-2005054188-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-06-16 | — | — | WO | claimed |
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2024-09-05 | — | — | US | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2022-07-14 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| CN-1906160-A | Imidazole derivatives, processes for preparing them and their uses | UCB SA (BE) | 2007-01-31 | — | — | CN | disclosed |
| EP-1706376-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | disclosed |
| WO-2005054188-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | PER2 1324/4885CNR2 1657/4885AGTR1 808/4885 |
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | PER2 251/4885CNR2 1010/4885AGTR1 2105/4885 |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | PER2 251/4885CNR2 1010/4885AGTR1 2105/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | PER2 276/4885CNR2 285/4885AGTR1 3890/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | PER2 1005/4885CNR2 2109/4885AGTR1 1569/4885 |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | PER2 4827/4885CNR2 1595/4885AGTR1 2515/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | PER2 467/4885CNR2 480/4885AGTR1 1489/4885 |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | PER2 4827/4885CNR2 1595/4885AGTR1 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.